Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma
NCT03399799Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Jul 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of talquetamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting Toxicity at 28 days and Adverse Events up to 2.10 years. Started Dec 2017; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03399799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399799.